Scalp psoriasis: A review of current topical treatment options

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 9, 2007, Pages 1151-1160

  Papp, K ^a   Berth Jones, J ^b   Kragballe, K ^c   Wozel, G ^d   de la Brassinne, M ^e  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Psoriasis; Scalp; Topical; Treatment

Indexed keywords

AMCINONIDE; ANTIFUNGAL AGENT; BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; COAL TAR; COLECALCIFEROL; CORTICOSTEROID; DESONIDE; DIFLORASONE DIACETATE; DITHRANOL; DITHRANOL DERIVATIVE; FLUOCINOLONE ACETONIDE; FLUTICASONE PROPIONATE; HALCINONIDE; HYDROCORTISONE 17 BUTYRATE 21 PROPIONATE; KERATOLYTIC AGENT; KETOCONAZOLE; MOMETASONE FUROATE; PLACEBO; PROPYLENE GLYCOL; PYRITHIONE ZINC; RETINOID DERIVATIVE; SALICYLIC ACID; TACALCITOL; TAZAROTENE; ULOBETASOL PROPIONATE; UNINDEXED DRUG;

CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DERMATOME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; MAGNETOTHERAPY; MICROSCOPIC ANATOMY; MONOTHERAPY; PATHOGENESIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; SCALP; SEBORRHEIC DERMATITIS; SKIN IRRITATION;

EID: 34548772864     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02424.x     Document Type: Review

References (83)

1. van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and manage. Am J Clin Dermatol 2001; 2: 159-165.
2. Farber EM, Nall L. Natural history and treatment of scalp psoriasis. Cutis 1992; 49: 396-400.
3. Dawber R, van Neste D. Hair and Scalp Disorders. Common Presenting Signs, Differential Diagnosis and Treatment, 1st edn. JB Lippincott, Philadelphia, 1995.
4. van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998; 197: 326-334.
5. Sulzberger MB, Obadia J. A modified liquid petrolatum preparation; its use in the management of certain common dermatoses of the scalp. AMA Arch Derm 1956; 73: 373-375.
6. Dellon AL. Long-term remission of psoriasis after dermatome shaving. Plast Reconstr Surg 1982; 70: 220-229.
7. Castelpietra R, Dal Conte G. Initial experiences in the treatment of psoriasis with pulsating magnetic fields. Minerva Med 1984; 75: 2381-2387.
8. Taneja A, Racette A, Gourgouliatos Z, Taylor CR. Broad-band UVB fiber-optic comb for the treatment of scalp psoriasis: A pilot study. Int J Dermatol 2004; 43: 462-467.
9. Taylor CR, Racette AL. A 308-nm excimer laser for the treatment of scalp psoriasis. Lasers Surg Med 2004; 34: 136-140.
10. Schaefer H, Riedelmayer TE. Skin Barrier: Principles of Percutaneous Absorption. Karger, Basel, 1996: 2001.
11. Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol 2005; 53 (Suppl. 1): S59-S69.
12. van de Kerkhof P, Salonen S-H, on behalf of the EUROPSO Patient Survey Study Group. Large-scale European survey of quality of life in patients with psoriasis: Second phase results on quality of life and treatment reported by 7,525 members of European psoriasis patient associations. Published by the European Federation of Psoriasis Foundations (EUROPSO), Helsinki, Finland. Available from: http://www.europso.org/ [accessed September 2006].
13. Krueger G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
14. Schoen MP, Boehncke WH. Psoriasis [Review]. N Engl J Med 2005; 352: 1899-1912.
15. Rajendran CP, Ledge SG, Rani KP, Madhavan R. Psoriatic arthritis. J Assoc Physicians India 2003; 51: 1065-1068.
16. van der Vleuten CJ, van de Kerkhof PC. Management of scalp psoriasis: guidelines for corticosteroid use in combination treatment. Drugs 2001; 61: 1593-1598.
17. Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson TL Jr. Skin diseases associated with Malassezia species. J Am Acad Dermatol 2004; 51: 785-798.
18. Faergemann J, Diehl U, Bergfelt L et al. Scalp psoriasis: Synergy between the Malassezia yeasts and skin irritation due to calcipotriol. Acta Derm Venereol 2003; 83: 438-441.
19. Farr PM, Krause LB, Marks JM, Shuster S. Response of scalp psoriasis to oral ketoconazole. Lancet 1985; 2: 921-922.
20. Nakayama J. Four cases of sebopsoriasis or seborrheic dermatitis of the face and scalp successfully treated with 1a-24 (R)-dihydroxycholecalciferol (tacalcitol) cream. Eur J Dermatol 2000; 10: 528-532.
21. Franz E. About the regression of psoriasis capitis after mechanical epilation (relations between the psoriatic efflorescence and the follicular proliferation). Arch Dermatol Res 1978; 263: 247-256.
22. Conti Diaz IA, Civila E, Veiga R. The importance of microscopic examination in the management of desquamative diseases of the scalp. Mycopathologia 2002; 153: 71-75.
23. Elewski BE. Clinical diagnosis of common scalp disorders. J Invest Dermatol Symp Proc 2005; 10: 190-193.
24. Larko O. Problem sites: Scalp, palm and sole, and nail. Dermatol Clin 1995; 13: 771-777.
25. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49 (Suppl.): S57-S61.
26. Jobling RG. Psoriasis - a preliminary questionnaire study of sufferers' subjective experience. Clin Exp Dermatol 1976; 1: 233-236.
27. Chen SC, Yeung J, Chren M-M. Scalpdex: A quality-of-life instrument for scalp dermatitis. Arch Dermatol 2002; 138: 803-807.
28. Farber EM, Harris DR. Hospital treatment of psoriasis. A modified anthralin program. Arch Dermatol 1970; 101: 381-389.
29. Høvding G. Treatment of psoriasis of the scalp with betamethasone 17,21-dipropionate plus salicylic acid lotion ('Diprosalic'). Pharmatherapeutica 1981; 3: 61-66.
30. Andreassi L, Giannetti A, Milani M, Scale Investigators Group. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: An open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol 2003; 148: 134-138.
31. Barnes L, Altmeyer P, Forstrom L, Stenstrom MH. Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol 2000; 10: 199-204.
32. Duweb G, Alhaddar J, Abuhamida M. Calcipotriol solution in scalp psoriasis. Int J Tissue React 2005; 27: 163-166.
33. Duweb GA, Abuzariba O, Rahim M, al-Taweel M, Abdullah SA. Scalp psoriasis: Topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. Int J Clin Pharmacol Res 2000; 20: 65-68.
34. Green C, Ganpule M, Harris D et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994; 130: 483-487.
35. Thaci D, Daiber W, Boehncke WH, Kaufmann R. Calcipotriol solution for the treatment of scalp psoriasis: Evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology 2001; 203: 153-156.
36. Franz TJ, Parsell DA, Myers JA, Hannigan JF. Clobetasol propionate foam 0.05%: A novel vehicle with enhanced delivery. Int J Dermatol 2000; 39: 535-538.
37. Griffiths CE, Finlay AY, Fleming CJ, Barker JN, Mizzi F, Arsonnaud S. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat 2006; 17: 90-95.
38. Housman TS, Keil KA, Mellen BG et al. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol 2003; 49: 79-82.
39. Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects quality of life: A randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003; 72: 407-411.
40. Jarratt M, Breneman D, Gottlieb AB, Poulin Y, Liu Y, Foley V. Clobetasol propionate shampoo 0.05%: A new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004; 3: 367-373.
41. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 2003; 7: 185-192.
42. Langner A, Wolska H, Hebborn P. Treatment of psoriasis of the scalp with coal tar gel and shampoo preparations. Cutis 1983; 32: 295-296.
43. Wulff-Woesten A, Ohlendorf D, Henz BM, Haas N. Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp. Skin Pharmacol Physiol 2004; 17: 91-97.
44. Pauporte M, Maibach H, Lowe N et al. Fluocinolone acetonide topical oil for scalp psoriasis. J Dermatolog Treat 2004; 15: 360-364.
45. Huriez C, de Mersseman-Dorchies J. Treatment of psoriasis of the scalp and skin folds with a fluocinolone-propylene glycol combination. Lille Med 1967; 12 (Suppl.): 1270-1274.
46. Johannesson A, Lindelof B. The effect of Grenz rays on psoriasis lesions of the scalp: A double blind bilateral trial. Photodermatol 1985; 2: 388-391.
47. Johannesson A, Lindelof B. Additional effect of Grenz rays on psoriasis lesions of the scalp treated with topical corticosteroids. Dermatologica 1987; 175: 290-292.
48. Lindelof B, Johannesson A. Psoriasis of the scalp treated with Grenz rays or topical corticosteroid combined with Grenz rays. A comparative randomized trial. Br J Dermatol 1988; 119: 241-244.
49. Going SM, Guyer BM, Jarvie DR, Hunter JA. Salicylic acid gel for scalp psoriasis. Clin Exp Dermatol 1986; 11: 260-262.
50. Ross SD, Schachter RK. A randomized comparison of three conventional modes of treatment of psoriasis of the scalp. Cutis 1981; 28: 438-439.
51. Ruzicka T, Trompke C. Treatment of scalp psoriasis. An effective and safe tacalcitol emulsion. Hautarzt 2004; 55: 165-170.
52. Aste N. Tacalcitol ointment in the treatment of psoriasis. G Ital Dermatol Venereol 2004; 139: 81-84.
53. Shemer A, Nathansohn N, Kaplan B, Weiss G, Newman N, Trau H. Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. Int J Dermatol 2000; 39: 532-534.
54. Musulmeci ML, Pulvirenti N, Tedeschi A et al. Uso di un topico a base di urea ad azione cheratolitica nella psoriasi. Giorn Derm Clin 2004; XXIV: 16-18.
55. Caccialanza M, Piccinno R, Cappio F, Rozza M, Mainardi L. Phototherapy of psoriasis of the scalp. Results in 21 patients treated with a special portable ultraviolet rays lamp. G Ital Dermatol Venereol 1989; 124: LXI-LXV.
56. Dotterud LK, Braun R. UV-B comb versus betamethasone solution in scalp psoriasis. Tidsskr Nor Laegeforen 2000; 120: 1858-1859.
57. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: A systematic review. Br J Dermatol 2002; 146: 351-364.
58. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003; 4: 221-224.
59. Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol 2005; 53 (Suppl. 1): S39-S49.
60. Reid DC, Kimball AB. Clobetasol propionate foam in the treatment of psoriasis. Expert Opin Pharmacother 2005; 6: 1735-1740.
61. Berth-Jones J, Chu AC, Dodd WA et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992; 127: 266-271.
62. Berth-Jones J, Bourke JF, Iqbal SJ, Hutchinson PE. Urine calcium excretion during treatment of psoriasis with topical calcipotriol. Br J Dermatol 1993; 129: 411-414.
63. Tham SN, Lun KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994; 131: 673-677.
64. Cunliffe WJ, Berth-Jones J, Claudy A et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992; 26: 736-743.
65. Kragballe K, Gjertsen BT, De Hoop D et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337: 193-196.
66. Ramsay CA, Berth-Jones J, Brundin G et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994; 189: 260-264.
67. Poyner T, Hughes JW, Dass BK et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. J Dermatolog Treat 1993; 4: 173-177.
68. Ellis JP, Griffiths WAD, Klaber MR. Long-term treatment of chronic plaque psoriasis with calcipotriol ointment in patients unresponsive to short-contact dithranol. Eur J Clin Res 1995; 7: 247-257.
69. Fenton C, Plosker GL. Calcipotriol/betamethasone diproprionate. A review of its use in the treatment of psoriasis vulgaris. Am J Clin Dermatol 2004; 5: 463-478.
70. Anstey AV, Kragballe K. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol 2006; 45: 970-975.
71. Kaufmann R, Bibby AJ, Bissonnette R et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205: 389-393.
72. Kragballe K, Austad J, Barnes L et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155-1160.
73. Kragballe K, van de Kerkhof PC. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 39-44.
74. Downs AMR. Overnight application of Daivobet® ointment is effective in scalp psoriasis. Br J Dermatol 2004; 151 (Suppl. 68): 52.
75. Emerson RM, Howlett C. Successful treatment of scalp psoriasis with Dovobet® ointment. Br J Dermatol 2004; 151 (Suppl. 68): 52-53.
76. Cassano N, Vena GA. Treatment of scalp psoriasis with the calcipotriol/ betamethasone dipropionate two compound product: A pilot open-label study. Presented at WPC 2006, Stockholm, Sweden, 2006.
77. Buckley C, Shapiro J, Saari S et al. Calcipotriol plus betamethasone dipropionate (LEO80185) gel is effective and safe in the treatment of scalp psoriasis (a phase II study). J Eur Acad Dermatol Venereol 2005; 19 (Suppl. 2): 175.
78. Haas N, Wulff-Woesten A, Sterry W, Meffert H. Dithranol in the treatment of scalp psoriasis. J Dtsch Dermatol Ges 2003; 1: 688-693.
79. Rosenberg EW, Belew PW. Improvement of psoriasis of the scalp with ketoconazole. Arch Dermatol 1982; 118: 370-371.
80. Jury CS, Hugh McL, Shankland GS et al. A randomized, placebo-controlled trial of oral itraconazole in scalp psoriasis. J Dermatol Treat 2000; 11: 85-89.
81. Braun R, Dotterud LK, Falk ES. Comparison of betamethasone valerate solution with phototherapy (UVB comb) in scalp psoriasis treatment. Acta Derm Venereol 1998; 78: 385.
82. Lindelof B. Grenz ray therapy in dermatology. An experimental, clinical and epidemiological study. Acta Derm Venereol Suppl (Stockh) 1987; 132: 1-67.
83. FouéréS, Furtado T. Assessment of patients' compliance with topical psoriasis treatments. Published by the European Federation of Psoriasis Foundations (EUROPSO), Helsinki, Finland. Available from: http://www.europso.org/ [accessed September 2006].